Affymetrix Chief Medical Officer to speak at AAAS on Personalized Medicine

Affymetrix, Inc., (Nasdaq: AFFX) today announced that its Chief Medical Officer, Dr. Rick Hockett, will address the topic of ‘Personalized Medicine: Planning for the Future’ at a meeting of the American Association for the Advancement of Science (AAAS) and the Food and Drug Law Institute (FDLI) on June 1 in Washington, DC.

Dr. Hockett will speak in a panel discussion at 10:15 AM Eastern time on ‘State of the Science: Connecting Biomarkers and Diagnostics.’ The panel will be chaired by Teri Manolio, Director of the Office of Population Genomics, at the National Institutes of Health. It will also include Leigh Anderson, CEO of the Plasma Proteome Institute, and David Borsook, Co-Director of the Imaging Consortium for Drug Development at McLean Hospital, Belmont, MA.

"Identifying biomarkers which increase the benefit-to-risk-ratio for medications allows doctors to provide more meaningful health outcomes for patients,” said Dr. Hockett. "One of the first examples of personalized medicine began when doctors utilized glucose measurements to diagnose diabetes and prescribe insulin. There are still many challenges ahead to developing similarly effective therapies for more complex diseases such as cancer. I am looking forward to discussing these and identifying a path forward with such distinguished colleagues.”

Before joining Affymetrix in March of this year, Dr. Hockett served as Medical Fellow and the Director of Genomic Medicine at Eli Lilly. Earlier he spent seven years on staff at the University of Alabama at Birmingham Hospital, with the positions of Assistant Professor of Pathology and Head of Clinical Immunology and Molecular Diagnostics.

This colloquium is free and open to the public. It will be held at the AAAS Headquarters, 1200 New York Avenue NW, Washington, DC. For more information visit: http://www.aaas.org/spp/PM/colloquia

About Affymetrix, Inc.

Affymetrix GeneChip^® microarray technology is the industry-standard tool for analyzing complex genetic information. After inventing microarray technology in the late 1980s, Affymetrix scientists have been dedicated to developing innovative products that provide researchers with a more complete view of the genome. These products continue to accelerate genetic research. They enable scientists to develop diagnostics which may support the tailoring of treatments for patients by identifying and measuring the genetic information associated with complex diseases.

Today, Affymetrix technology is used by the world’s top pharmaceutical, diagnostic, and biotechnology companies, as well as leading academic, government, and not-for-profit research institutes. More than 1,800 systems have been shipped around the world and more than 18,000 peer-reviewed papers have been published using the technology.

Affymetrix is headquartered in Santa Clara, Calif., and has manufacturing facilities in Cleveland, Ohio, and Singapore. The company has about 1,100 employees worldwide and maintains sales and distribution operations across Europe and Asia. For more information about Affymetrix, please visit the company’s website at www.affymetrix.com.

Forward-Looking Statements

All statements in this press release that are not historical are "forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix’ "expectations,” "beliefs,” "hopes,” "intentions,” "strategies” or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected, including, but not limited to: risks of the company’s ability to achieve and sustain higher levels of revenue, higher gross margins and reduced operating expenses; uncertainties related to technological approaches, manufacturing and product development; personnel retention; uncertainties related to cost and pricing of Affymetrix products; dependence on collaborative partners; uncertainties related to sole-source suppliers; risks associated with past and future acquisitions; uncertainties relating to FDA and other regulatory approvals; competition; risks relating to intellectual property of others and the uncertainties of patent protection and litigation. These and other risk factors are discussed in Affymetrix’ Form 10-K for the year ended December 31, 2008, and other SEC reports, including its Quarterly Reports on Form 10-Q for subsequent quarterly periods. Affymetrix expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Affymetrix’ expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

NOTE: Affymetrix, the Affymetrix logo and GeneChip^® are registered trademarks owned or used by Affymetrix Inc.